TNF-alpha inhibitors: screening, infection risk and injection teaching

How blocking TNF calms inflammation and lowers defences

Tumour necrosis factor alpha is a cytokine that drives joint destruction, gut inflammation and skin plaques. Adalimumab, certolizumab, etanercept, golimumab and infliximab bind or neutralise it, which reduces inflammation in rheumatoid arthritis, Crohn disease, ulcerative colitis and plaque psoriasis. Most are self-injected under the skin, while infliximab is given as an intravenous infusion in a monitored setting.

The same cytokine helps contain intracellular organisms and keeps old infections walled off. Blocking it can let a dormant infection reactivate or let a new one spread quickly. This is why the labels carry a boxed warning for serious infections, including tuberculosis, bacterial sepsis and invasive fungal infections, and why the class sits beside other immunosuppressants in exam questions about infection risk.

Screening before the first dose

Before treatment starts, the patient is evaluated for latent tuberculosis, and hepatitis B status is checked because the virus can reactivate during therapy. A positive screen does not automatically mean treatment is cancelled; the prescriber may treat the latent infection first. The nurse confirms results are documented and asks about travel, residence in areas with endemic fungal infections, and recent exposure to tuberculosis.

Screening is not a one-time event. The adalimumab label advises watching for tuberculosis during treatment even when the initial test was negative, and monitoring hepatitis B carriers during and for several months after therapy. Ask about heart failure and demyelinating disease such as multiple sclerosis, because new or worsening heart failure and neurological reactions are listed warnings that the prescriber needs to weigh.

Document the screening results, the date of the last tuberculosis assessment and the hepatitis B status in a place every clinician can find. Patients often see several specialists, and a clear record prevents repeated tests or, worse, a missed reactivation risk when a new prescriber adds another immunosuppressant.

Infection cues, vaccines and other hold-and-report triggers

Teach the patient to report fever, cough, night sweats, weight loss, painful urination, warm red skin or any infection that is not improving. A dose is usually withheld during an active serious infection, but the decision belongs to the prescriber, so the nurse reports rather than simply skipping. Signs of infection may be blunted, so a modest temperature or new cough deserves attention.

Live vaccines should be avoided during treatment, and other vaccines are best brought up to date before starting. Infants exposed in pregnancy may need some vaccines delayed, so the paediatric team should know. Other report triggers include new rash with joint pain suggesting a lupus-like reaction, unexplained bruising or pallor suggesting cytopenias, jaundice, new numbness or vision change, and worsening breathlessness or ankle swelling.

Teaching safe self-injection and infusion monitoring

For prefilled pens and syringes, teach storage in the refrigerator, letting the device reach room temperature before injecting rather than warming it, and rotating sites such as the thigh and abdomen. Avoid tender, bruised, red or hard skin. Mild redness or itching at the site is common; spreading redness, pus or fever is not. Use teach-back with the actual device.

Infliximab infusions can cause allergic reactions during the infusion and for a period afterwards, so the patient is observed and asked to report hives, swelling of the face or throat, breathing difficulty, chest pain or dizziness. Remind every patient on this class to tell surgeons and dentists about the medicine, and to carry a list of current immunosuppressants when seeking care.

Worked exam-style scenario

Imagine a hypothetical patient with Crohn disease due for a scheduled adalimumab injection who reports three days of fever and a productive cough. Options include giving the dose because it is due, giving it and advising rest, holding it and contacting the prescriber, or sending the patient home to try fluids. Holding and reporting is the strongest answer because active infection is a key hold trigger.

Giving the dose ignores the boxed warning. Advising fluids alone underestimates how quickly infection can progress in an immunosuppressed patient. A second version asks which vaccine the patient may receive on this therapy; an inactivated vaccine fits, whereas a live attenuated vaccine does not. Exam reasoning rewards linking reduced immune defence to every decision on the page.

Sources and further reading

DailyMed: HUMIRA (adalimumab) prescribing information. Boxed warning on serious infections, TB evaluation and monitoring, hepatitis B reactivation, heart failure, neurological reactions and live vaccine avoidance.

MedlinePlus: Infliximab injection. Infusion reactions and observation, serious viral, bacterial and fungal infection risk, and endemic fungal exposure history.

MSD Manual Professional: Rheumatoid arthritis. TNF inhibitors as biologic DMARDs, reactivation of latent TB, hepatitis B and fungal infection, and updating vaccinations before biologics.